Neutron Analysis of Glaucoma Drugs Could Help Aggressive Cancer Drug Design

News   Feb 13, 2018 | Original story from Oak Ridge National Laboratory

 
Neutron Analysis of Glaucoma Drugs Could Help Aggressive Cancer Drug Design

This image shows the active site of hCA II. The active site is flanked by hydrophilic (violet) and hydrophobic (green) binding pockets that can be used to design specific drugs targeting cancer-associated hCAs. Five clinical drugs are shown superimposed in the hCA II active site, based on room-temperature neutron structures. Credit: (ORNL/Andrey Kovalevsky)

 
 
 

RELATED ARTICLES

Sweet Spot of Activity in Immune System Key to Fighting Cancer

News

Scientists have shown how stimulating a specific location on the surface of immune cells can be targeted with antibodies to help in their fight against cancer.

READ MORE

Compound Offers Pain-relief of Opioids Without Addictive Properties

News

Researchers have engineered a new compound that animal tests suggest could offer the pain-relieving properties of opioids such as morphine and oxycodone without the risk of addiction.

READ MORE

E. Coli’s Internal Bomb Offers Chink In Armour

News

Bacteria's internal bomb, the so-called toxin-antitoxin (TA) system that is part of the normal bacterial makeup, may be triggered to make bacteria turn on themselves, providing a valuable target for novel antimicrobial approaches in drug design.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Analysis & Separations Cancer Research Informatics

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE